Zanidatamab induces response in refractory HER2-positive biliary tract cancer

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.The agent also exhibited a manageable safety profile, investigators who conducted the phase 2b HERIZON-BTC-01 study concluded.“The findings demonstrate that HER2 is a very viable target in this disease, and targeting it can lead to clinically significant responses,” researcher Shubham Pant, MD, MBBS, associate professor in the department of gastrointestinal medical oncology at The University ofRead More